Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR7280 Food Effect and QT Study
NCT06969664Phase 1Completed
- Sponsor
- Hengrui
- Start
- May 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SHR7280 in endometriosis and Uterine Fibroids (UF) (2 arms), sponsored by Hengrui. Primary endpoints: Peak concentration, Area under the plasma concentration-time curve from time 0 to the last quantifiable timepoint and 1 more. Started May 2025; status: completed.
02
Drugs
SHR7280
03
Conditions
endometriosisUterine Fibroids (UF)
Beyond the preview
Go deeper on NCT06969664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06969664.